Evidence map›Paper›PMID 40691296›Full record

ArticleAnalytical and bioanalytical chemistry2025

Ultrasensitive electrochemical immunosensor system for the determination of CD133 biomarker.

Ahmet Cetinkaya, Bilal Kızılelma, Nazila Farhangzad, Elif Dener-Kılıç, Goksu Ozcelikay-Akyıldız, Tülin Özkan, Mehmet Altay Unal, Asuman Sunguroglu, Sibel A Ozkan

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ahmet CetinkayaGülhane Faculty of Pharmacy, Department of Analytical Chemistry, University of Health Sciences, Ankara, Türkiye.
Bilal KızılelmaASELSAN Inc, Ankara, Türkiye.
Nazila FarhangzadFaculty of Medicine, Department of Medical Biology, Ankara University, Ankara, Türkiye.
Elif Dener-KılıçFaculty of Medicine, Department of Medical Biology, Ankara University, Ankara, Türkiye.
Goksu Ozcelikay-AkyıldızFaculty of Pharmacy, Department of Analytical Chemistry, Ankara University, Ankara, Türkiye.
Tülin ÖzkanFaculty of Medicine, Department of Medical Biology, Ankara University, Ankara, Türkiye.
Mehmet Altay UnalStem Cell Institute, Ankara University, Ankara, Türkiye.
Asuman SungurogluFaculty of Medicine, Department of Medical Biology, Ankara University, Ankara, Türkiye. sunguroglu.asuman@gmail.com.
Sibel A OzkanFaculty of Pharmacy, Department of Analytical Chemistry, Ankara University, Ankara, Türkiye. ozkan@pharmacy.ankara.edu.tr.ORCID http://orcid.org/0000-0001-7494-3077

Funding

The Scientific and Technological Research Council of Türkiye, TUBITAK 1004 Project Project number: 20AG003
6 · The paper itself

Abstract

Cancer stem cells (CSCs) have recently emerged as important variables affecting the development or invasiveness of solid tumors. Prominin 1 (PROM1, CD133) is a frequently used CSC biomarker in various tumors, including lung cancer, and CD133 overexpression is linked to chemoresistance, cancer recurrence, and a poor prognosis. Furthermore, CD133 has a significant impact on tumor growth and metastasis. In this work, the detection of CD133 using a single-use multi-walled carbon nanotube (MWCNT)-supported immunoplatform was achieved for the first time. The immunoplatform was designed using an anti-CD133 antibody and the CD133 protein. Differential pulse voltammetry (DPV) measurements were performed between -0.20 V and 0.8 V using a 5.0 mM [Fe(CN)

Indexed as

AC133 AntigenBiomarkers, TumorBiosensing TechniquesElectrochemical TechniquesHumansImmunoassayLimit of DetectionNanotubes, CarbonAC133 AntigenBiomarkers, TumorNanotubes, CarbonPROM1 protein, humanCancer stem cellsCD133ImmunosensorMWCNT-supported immunoplatformReal samples

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.